Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Even if these drugs do not pose a threat as a direct competitor, the expected decline in obesity rates will inevitably lead to a shift in healthcare demands
What the findings mean for treatment Current clinical guidelines recommend both GLP-1RAs and SGLT-2 inhibitors for people with type 2 diabetes who have established or high-risk cardiovascular disease, including PAD
As discussed below, it is important to consider the pharmacokinetic properties of metformin when extrapolating data from in vitro studies to potential benefits when used clinically
That is why access to these medications through a doctor supervised weight loss program is so important
Members can now get a range of free tools from Noom designed to address all of these concerns, plus additional habit-building features for results that last
